Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > FDA guides on how AA can be converted to full approval.

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Mar 24, 2023 12:48pm

240 Views

Post# 35358904

RE:RE:RE:FDA guides on how AA can be converted to full approval.

"Stuff" is happening around ONCY - and its being regulated by the FDA's timeline.

Now that Big Pharma has a clear understanding on how they can take ONCY's 2 Phase 3 clinical trials through to FULL APPROVAL using the FDA's new "one-trial" approach ... "stuff" should really be ramping-up on the acquisition front for ONCY - which could well be worth US$8-10 Billion

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"